Yusheng Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yusheng Guo has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Lian Yang
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications Chanyuan Liu
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publicationChuansheng Zheng
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication- Chuansheng Zheng
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication Chunbo Wang
Department of Energy Power & Mechanical Engineering, North China Electric Power University, Baoding, 071003, China
1 shared publicationDingyuan Cheng
Medical School of Chinese PLA, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 12 October 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (10) , e014952
AI-derived 3D body composition predicts prognosis of chemoimmunotherapy in small cell lung cancer: a multicenter study
Background Small cell lung cancer (SCLC) has a poor prognosis despite standard first-line chemoimmunotherapy. Reliable, non-invasive biomarkers for risk stratification are urgently needed. Three-dimensional (3D) body composition (BC) analysis from chest CT scans offers a promising approach to assess systemic metabolic status.Methods In this multicenter study, we analyzed patients treated with first-line chemoimmunotherapy across five institutions. Using a deep learning model, 3D BC parameters were automatically extracted from baseline chest CTs. We evaluated their associations with overall survival (OS) and progression-free survival using Kaplan-Meier and Cox regression analyses. A total of 101 machine learning model configurations were evaluated to develop predictive models, and the SHapley Additive exPlanations method was applied to enhance model interpretability. Additionally, we investigated the association between BC parameters and CD8 + T-cell infiltration in the tumor microenvironment.Results Among 575 patients (training: 161; internal validation: 69; external validation: 345), all four 3D BC indices significantly stratified OS. Multivariable Cox analysis showed that higher skeletal muscle volume index was independently associated with better OS (HR=0.956, 95% CI 0.928 to 0.985, p=0.003), whereas higher visceral fat volume index was associated with worse OS (HR=1.017, 95% CI 1.002 to 1.032, p=0.026). 3D BC provided more pronounced prognostic stratification than conventional two-dimensional measures and body mass index. The selected linear discriminant analysis model achieved area under the curves of 0.756, 0.781, and 0.783 in the training, internal validation, and external validation cohorts, respectively. In an exploratory subset of 35 patients, higher skeletal muscle volume index was associated with increased intratumoral CD8+T cell density.Conclusions Higher skeletal muscle volume index was associated with better OS, whereas higher visceral fat volume index was associated with worse OS. Automated 3D BC may provide complementary non-invasive prognostic information in patients with SCLC receiving first-line chemoimmunotherapy.
- 12 October 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (10) , e014952
Open AccessAI-derived 3D body composition predicts prognosis of chemoimmunotherapy in small cell lung cancer: a multicenter study
Background Small cell lung cancer (SCLC) has a poor prognosis despite standard first-line chemoimmunotherapy. Reliable, non-invasive biomarkers for risk stratification are urgently needed. Three-dimensional (3D) body composition (BC) analysis from chest CT scans offers a promising approach to assess systemic metabolic status.Methods In this multicenter study, we analyzed patients treated with first-line chemoimmunotherapy across five institutions. Using a deep learning model, 3D BC parameters were automatically extracted from baseline chest CTs. We evaluated their associations with overall survival (OS) and progression-free survival using Kaplan-Meier and Cox regression analyses. A total of 101 machine learning model configurations were evaluated to develop predictive models, and the SHapley Additive exPlanations method was applied to enhance model interpretability. Additionally, we investigated the association between BC parameters and CD8 + T-cell infiltration in the tumor microenvironment.Results Among 575 patients (training: 161; internal validation: 69; external validation: 345), all four 3D BC indices significantly stratified OS. Multivariable Cox analysis showed that higher skeletal muscle volume index was independently associated with better OS (HR=0.956, 95% CI 0.928 to 0.985, p=0.003), whereas higher visceral fat volume index was associated with worse OS (HR=1.017, 95% CI 1.002 to 1.032, p=0.026). 3D BC provided more pronounced prognostic stratification than conventional two-dimensional measures and body mass index. The selected linear discriminant analysis model achieved area under the curves of 0.756, 0.781, and 0.783 in the training, internal validation, and external validation cohorts, respectively. In an exploratory subset of 35 patients, higher skeletal muscle volume index was associated with increased intratumoral CD8+T cell density.Conclusions Higher skeletal muscle volume index was associated with better OS, whereas higher visceral fat volume index was associated with worse OS. Automated 3D BC may provide complementary non-invasive prognostic information in patients with SCLC receiving first-line chemoimmunotherapy.
- Open Access
Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review
Background: A number of studies have reported an association between the dynamics of neutrophil-to-lymphocyte ratio (NLR) and clinical efficacy in patients treated with immune checkpoint inhibitors (ICIs), but there is still a lack of a meta-analysis or systematic review. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched until September 2022 for studies reporting on the association between the change in NLR after ICI treatment and clinical outcomes. Outcome measures of interest included: change in NLR before and after treatment, overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Results: A total of 4154 patients in 38 studies were included. The pooled percentage of patients with increased NLR was 49.7% (95CI%: 43.7–55.8%). Six studies discussing the change in NLR in patients with different tumor responses all showed that the NLR level in patients without response to immunotherapy may increase after ICI treatment. The upward trend in NLR was associated with shorter OS (pooled HR: 2.05, 95%CI: 1.79–2.35, p < 0.001) and PFS (pooled HR: 1.89, 95%CI: 1.66–2.14, p < 0.001) and higher ORR (pooled OR: 0.27, 95%CI: 0.19–0.39, p < 0.001), and downward trend in NLR was associated with longer OS (pooled HR: 0.49, 95%CI: 0.42–0.58, p < 0.001) and PFS (pooled HR: 0.55, 95%CI: 0.48–0.63, p < 0.001) and lower ORR (pooled OR: 3.26, 95%CI: 1.92–5.53, p < 0.001). In addition, post-treatment high NLR was associated with more impaired survival than baseline high NLR (pooled HR of baseline high NLR: 1.82, 95%CI: 1.52–2.18; pooled HR of post-treatment high NLR: 2.93, 95%CI: 2.26–3.81), but the NLR at different time points may have a similar predictive effect on PFS (pooled HR of baseline high NLR: 1.68, 95%CI: 1.44–1.97; pooled HR of post-treatment high NLR: 2.00, 95%CI: 1.54–2.59). Conclusions: The NLR level of tumor patients after ICI treatment is stable overall, but the NLR level in patients without response to immunotherapy may increase after ICI treatment. Patients with an upward trend in NLR after ICI treatment were associated with worse clinical outcomes; meanwhile, the downward trend in NLR was associated with better clinical outcomes. Post-treatment high NLR was associated with more impaired survival than baseline high NLR.
Open AccessFocus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review
Background: A number of studies have reported an association between the dynamics of neutrophil-to-lymphocyte ratio (NLR) and clinical efficacy in patients treated with immune checkpoint inhibitors (ICIs), but there is still a lack of a meta-analysis or systematic review. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched until September 2022 for studies reporting on the association between the change in NLR after ICI treatment and clinical outcomes. Outcome measures of interest included: change in NLR before and after treatment, overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Results: A total of 4154 patients in 38 studies were included. The pooled percentage of patients with increased NLR was 49.7% (95CI%: 43.7–55.8%). Six studies discussing the change in NLR in patients with different tumor responses all showed that the NLR level in patients without response to immunotherapy may increase after ICI treatment. The upward trend in NLR was associated with shorter OS (pooled HR: 2.05, 95%CI: 1.79–2.35, p < 0.001) and PFS (pooled HR: 1.89, 95%CI: 1.66–2.14, p < 0.001) and higher ORR (pooled OR: 0.27, 95%CI: 0.19–0.39, p < 0.001), and downward trend in NLR was associated with longer OS (pooled HR: 0.49, 95%CI: 0.42–0.58, p < 0.001) and PFS (pooled HR: 0.55, 95%CI: 0.48–0.63, p < 0.001) and lower ORR (pooled OR: 3.26, 95%CI: 1.92–5.53, p < 0.001). In addition, post-treatment high NLR was associated with more impaired survival than baseline high NLR (pooled HR of baseline high NLR: 1.82, 95%CI: 1.52–2.18; pooled HR of post-treatment high NLR: 2.93, 95%CI: 2.26–3.81), but the NLR at different time points may have a similar predictive effect on PFS (pooled HR of baseline high NLR: 1.68, 95%CI: 1.44–1.97; pooled HR of post-treatment high NLR: 2.00, 95%CI: 1.54–2.59). Conclusions: The NLR level of tumor patients after ICI treatment is stable overall, but the NLR level in patients without response to immunotherapy may increase after ICI treatment. Patients with an upward trend in NLR after ICI treatment were associated with worse clinical outcomes; meanwhile, the downward trend in NLR was associated with better clinical outcomes. Post-treatment high NLR was associated with more impaired survival than baseline high NLR.
- 11 August 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (4) , E64-E65
Letter to the Editor: Overlooking the important factor: Hypoxia
- 11 August 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (4) , E64-E65
Letter to the Editor: Overlooking the important factor: Hypoxia